<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394510</url>
  </required_header>
  <id_info>
    <org_study_id>NACStudy001</org_study_id>
    <nct_id>NCT01394510</nct_id>
  </id_info>
  <brief_title>Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes</brief_title>
  <official_title>Effect of Anti-oxidants on Beta-cell Function in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Utzschneider, Kristina, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Utzschneider, Kristina, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin is secreted by cells in the pancreas called beta-cells. Beta-cell dysfunction is a
      critical feature of type 2 diabetes (T2DM). High glucose levels can exacerbate beta-cell
      dysfunction with oxidative stress proposed as a major mediator of this &quot;glucotoxic&quot; effect.
      High glucose levels have also been shown to contribute to vascular dysfunction and
      inflammation and these adverse responses decreased with the use of antioxidants. The
      hypothesis is that antioxidants improve beta-cell function in individuals with elevated
      glucose levels by decreasing oxidative stress. In this study the investigators will
      specifically test whether the antioxidant N-acetylcysteine (NAC) can improve beta-cell
      function in individuals with type 2 diabetes by decreasing oxidative stress.

      This study will be a dose finding study to determine the tolerability of 600 mg versus 1200
      mg twice a day of NAC and the effects on beta-cell function, glucose tolerance and oxidative
      stress markers in persons with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta-cell dysfunction is a critical feature of type 2 diabetes (T2DM). High glucose levels
      can exacerbate beta-cell dysfunction with oxidative stress proposed as a major mediator of
      this &quot;glucotoxic&quot; effect. High glucose levels have also been shown to contribute to vascular
      dysfunction and inflammation and these adverse responses decreased with the use of
      antioxidants. The hypothesis is that antioxidants improve beta-cell function in individuals
      with elevated glucose levels by decreasing oxidative stress. In this study the investigators
      will specifically test whether the antioxidant N-acetylcysteine (NAC) can improve beta-cell
      function in individuals with type 2 diabetes by decreasing oxidative stress.

      This initial study will be a dose finding study to determine the tolerability of 600 mg
      versus 1200 mg twice a day of NAC and the effects of NAC treatment on beta-cell function,
      glucose tolerance and oxidative stress markers in persons with type 2 diabetes. Study
      procedures will include a fasting urine sample and performance of a 2 hour 75 gram oral
      glucose tolerance test at baseline, after 2 weeks on 600 mg twice daily NAC and again after 2
      more weeks on 1200 mg NAC twice a day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Urine F2 Alpha Isoprostane Levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in fasting urine isoprostane levels at 4 weeks vs baseline as a marker of oxidative stress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Glucose (AUCg)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in AUCg from 0-120 minutes during the oral glucose tolerance test at 4 weeks compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Disposition Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>The change in the oral disposition index defined was the change in the early insulin response divided by the change in glucose from 0-30 minutes during the oral glucose tolerance test divided by fasting insulin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine dose study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
    <arm_group_label>N-acetylcysteine dose study</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Uncontrolled diabetes mellitus with severe hyperglycemia (hemoglobin A1C ≥ 9%)

          -  Patients with diabetes mellitus who are taking insulin or glucose-lowering agents
             other than metformin

          -  Chronic oral or parenteral corticosteroid treatment (&gt;7 consecutive days of treatment)
             within 8 weeks prior to screening

          -  Use of human immunodeficiency virus (HIV) protease inhibitors or niacin

          -  Chronic inflammatory diseases or use of anti-inflammatory drugs.

          -  Thyroid abnormalities (thyroid-stimulating hormone [TSH] &lt;0.5 or &gt;5 µU/ml)

          -  Creatinine &gt;1.5 in men and &gt;1.3 mg/dl in women

          -  History of dysphagia, gastroparesis, gastric ulcer, malabsorption, swallowing
             disorders or intestinal motility disorder

          -  Gastroesophageal reflux disease (heartburn) requiring treatment.

          -  Active cancer

          -  Clinical hepatic disease or alanine aminotransferase (ALT) greater than ≥ 1.5 times
             upper limit of normal within 60 days preceding the first dose of the study drug

          -  Weight loss of &gt;5% body weight within the last 6 months, or starting an intensive
             exercise program within 4 weeks of study initiation

          -  Smoke or use tobacco

          -  Excessive alcohol consumption (&gt;2 drinks a day)

          -  Use of any investigational drug in the last 30 days

          -  Anemia (hematocrit &lt;33%), donation of one unit (500 ml) or more of blood, significant
             blood loss equaling at least one unit of blood within the past 2 weeks or a blood
             transfusion within 8 weeks prior to screening

          -  Employment by the research center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Utzschneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Szkudlinska MA, von Frankenberg AD, Utzschneider KM. The antioxidant N-Acetylcysteine does not improve glucose tolerance or β-cell function in type 2 diabetes. J Diabetes Complications. 2016 May-Jun;30(4):618-22. doi: 10.1016/j.jdiacomp.2016.02.003. Epub 2016 Feb 5.</citation>
    <PMID>26922582</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <results_first_submitted>May 10, 2016</results_first_submitted>
  <results_first_submitted_qc>May 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2016</results_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Utzschneider, Kristina, M.D.</investigator_affiliation>
    <investigator_full_name>Kristina Utzschneider, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>insulin secretion</keyword>
  <keyword>beta-cell function</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study sample size is very small. The data will be made available upon request.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine Dose Study</title>
          <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with type 2 diabetes either on metformin alone or treated with diet and lifestyle only.</population>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine Dose Study</title>
          <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass index</title>
          <description>Body mass index</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.17" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>metformin</title>
          <description>number of patients taking metformin</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Urine F2 Alpha Isoprostane Levels</title>
        <description>Change in fasting urine isoprostane levels at 4 weeks vs baseline as a marker of oxidative stress</description>
        <time_frame>4 weeks</time_frame>
        <population>Change in urine F2 alpha isoprostanes/mg urine creatinine. Urine isoprostanes were only measured in a subset of participants due to lack of effect of the intervention on glucose tolerance.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Dose Study</title>
            <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Urine F2 Alpha Isoprostane Levels</title>
          <description>Change in fasting urine isoprostane levels at 4 weeks vs baseline as a marker of oxidative stress</description>
          <population>Change in urine F2 alpha isoprostanes/mg urine creatinine. Urine isoprostanes were only measured in a subset of participants due to lack of effect of the intervention on glucose tolerance.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.089" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve for Glucose (AUCg)</title>
        <description>Change in AUCg from 0-120 minutes during the oral glucose tolerance test at 4 weeks compared to baseline</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Dose Study</title>
            <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Glucose (AUCg)</title>
          <description>Change in AUCg from 0-120 minutes during the oral glucose tolerance test at 4 weeks compared to baseline</description>
          <units>mg/dl x 120 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1011" spread="10922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Disposition Index</title>
        <description>The change in the oral disposition index defined was the change in the early insulin response divided by the change in glucose from 0-30 minutes during the oral glucose tolerance test divided by fasting insulin.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Dose Study</title>
            <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Disposition Index</title>
          <description>The change in the oral disposition index defined was the change in the early insulin response divided by the change in glucose from 0-30 minutes during the oral glucose tolerance test divided by fasting insulin.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine Dose Study</title>
          <description>Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristina Utzschneider, MD</name_or_title>
      <organization>VA Puget Sound Health Care System</organization>
      <phone>206-277-3568 ext 6-3568</phone>
      <email>kutzschn@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

